Detection of Clopidogrel Hyporesponsiveness Using a Point-of-Care Assay and the Impact of Additional Cilostazol Administration after Coronary Stent Implantation in Diabetic Patients
Open Access
- 1 January 2011
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 26 (2), 145-152
- https://doi.org/10.3904/kjim.2011.26.2.145
Abstract
Impaired responsiveness to clopidogrel is common in patients with type 2 diabetes mellitus (DM). The aim of this study was to evaluate the clinical application of a point-of-care assay to detect impaired responsiveness to clopidogrel after coronary stent implantation in patients with type 2 DM. We measured P2Y12 reaction units (PRU) with the VerifyNow point-of-care assay in 544 consecutive patients undergoing dual or triple (i.e., dual plus cilostazol) anti-platelet therapy after coronary stent implantation. High platelet reactivity (HPR) was defined as a PRU value ≥ 240. The mean PRU values were 233.5 ± 83.2 and 190.3 ± 85.5 in patients undergoing dual or triple anti-platelet therapy, respectively (p < 0.001). Patients with DM manifested higher post treatment PRU values (238.3 ± 82.4 vs. 210.8 ± 86.8, p = 0.001) and a higher frequency of HPR (44.8% vs. 31.0%, p = 0.003) as compared to patients without DM. We also found that higher PRU values and a higher frequency of HPR were present in patients with DM who were undergoing both triple and dual anti-platelet therapy. However, the higher post-treatment PRU values observed in patients with DM decreased with triple anti-platelet therapy (219.4 ± 82.5 vs. 247.9 ± 81.1, p = 0.044). A point-of-care assay can detect elevated platelet reactivity and impaired responsiveness to clopidogrel in patients with type 2 DM. The addition of cilostazol to dual anti-platelet therapy may decrease post-treatment PRU values in patients with type 2 DM.Keywords
This publication has 30 references indexed in Scilit:
- Effects of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) on Platelet Aggregation and P-Selectin Expression in Patients Undergoing Coronary Artery Stent ImplantationThe American Journal of Cardiology, 2007
- Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel TreatmentDiabetes, 2005
- Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting StentsJAMA, 2005
- Effects of Cilostazol on Platelet Activation in Coronary Stenting Patients Who Already Treated with Aspirin and ClopidogrelThe Korean Journal of Internal Medicine, 2004
- Platelet activation in type 2 diabetes mellitusJournal of Thrombosis and Haemostasis, 2004
- The Platelet in DiabetesDiabetes Care, 2003
- Platelet Dysfunction in Type 2 DiabetesDiabetes Care, 2001
- Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial InfarctionCirculation, 2000
- Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial InfarctionJournal of the American College of Cardiology, 1997
- Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel DiseaseThe New England Journal of Medicine, 1996